PT  - JOURNAL ARTICLE
AU  - Álvarez-Díaz, Diego A.
AU  - Muñoz, Ana Luisa
AU  - Herrera-Sepúlveda, María T.
AU  - Tavera-Rodríguez, Pilar
AU  - Laiton-Donato, Katherine
AU  - Franco-Muñoz, Carlos
AU  - Ruiz-Moreno, Héctor Alejandro
AU  - Pelaez-Carvajal, Dioselina
AU  - Muñoz-Suarez, Alejandra M.
AU  - Galindo, Marisol
AU  - Reales-Gonzalez, Jhonnatan
AU  - Catama, Jenssy D.
AU  - De Arco, Beatriz Helena
AU  - Cobos, Tatiana
AU  - Arias-Ramirez, Edgar J.
AU  - Mercado-Reyes, Marcela
TI  - Neutralizing responses in fully vaccinated with BNT162b2, CoronaVac, ChAdOx1, and Ad26.COV2.S against SARS-CoV-2 lineages in Colombia, 2020-2021
AID  - 10.1101/2022.03.15.22272371
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.15.22272371
4099  - http://medrxiv.org/content/early/2022/03/15/2022.03.15.22272371.short
4100  - http://medrxiv.org/content/early/2022/03/15/2022.03.15.22272371.full
AB  - Background By March 2022, around 34 million people in Colombia had received a complete scheme of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including, mRNA-based vaccines, viral vectored coronavirus vaccines, or the inactivated whole virus vaccine. However, as several SARS-CoV-2 variants of concern (VOC) and interest (VOI) co-circulate in the country, determining the resistance level to vaccine-elicited neutralizing antibodies (nAbs) is useful to improve the efficacy of COVID-19 vaccination programs.Methods Microneutralization assays with the most prevalent SARS-CoV-2 lineages in Colombia during 2020-2021 were performed using serum samples from immunologically naïve individuals between 9 and 13 weeks after receiving complete regimens of CoronaVac, BNT162b2, ChAdOx1, or Ad26.COV2.S. The mean neutralization titer (MN50) was calculated by the Reed–Muench method and used to determine differences in vaccine-elicited nAbs against the SARS-CoV-2 lineages B.1.111, P.1 (Gamma), B.1.621 (Mu), and AY.25.1 (Delta).Results The most administered vaccines in the country, BNT162b2 and CoronaVac, elicited significantly different nAb responses against Mu, as the GMTs were 75.7 and 5.9-fold lower relative to the control lineage (B.1.111), while for Delta were 15.8 and 1.1-fold lower, respectively. In contrast, nAb responses against Mu and Delta were comparable between ChAd0×1-s and Ad26.COV2.S as the GMTs remained around 5 to 7-fold lower relative to B.1.111.Conclusions The emergence of SARS-CoV-2 variants in Colombia with a significant capacity to escape from vaccine-elicited nAbs indicates that a booster dose is highly recommended. Furthermore, other non-pharmacological measures should be retained in the vaccinated population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Sistema General de Regalias (SGR), project code BPIN 2020000100151. The Unidad Nacional para la Gestion del Riesgo de Desastres (UNGRD) Decreto Legislativo 559. Enterritorios COL-H-ENTerritorio 1840 (Convenio No. 219139).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Serum and nasopharyngeal swab samples were collected from individuals with written informed consent approved by the Ethics Committee of the Colombian National Health Institute (CEMIN)-04-2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors